CSTL · Castle Biosciences, Inc.
$25.48
+2.70% last session
End-of-day data · updated 2026-07-25
Market cap
$1B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-25.8
Dividend yield
—
Beta
1.00
Avg volume
0M
Employees
1K
2D change
-3.12%
5D change
3.31%
10D change
2.77%
30D change
7.75%
60D change
25.37%
MTD change
-0.10%
YTD change
-36.54%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — CSTL
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-06-25
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-25 | Roth Capital | Initiates | Buy | $0.00 → $40.00 |
| 2026-05-13 | BTIG | Maintains | Buy | $50.00 → $40.00 |
| 2026-05-07 | Baird | Maintains | Outperform | $44.00 → $43.00 |
| 2026-04-20 | Canaccord Genuity | Maintains | Buy | $50.00 → $40.00 |
| 2026-02-27 | Baird | Maintains | Outperform | $41.00 → $44.00 |
| 2026-01-26 | Guggenheim | Maintains | Buy | $43.00 → $47.00 |
| 2026-01-12 | Lake Street | Maintains | Buy | $35.00 → $52.00 |
| 2026-01-05 | Guggenheim | Maintains | Buy | $30.00 → $43.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-23
- RSI (14): RSI is 65 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 16.4% above the 50-day MA ($21.89).
- Price vs 200-day MA: Trading 11.5% below the 200-day MA ($28.80).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is positive (+0.07) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($14.65) and high ($43.04).
CSTL Price Chart
Loading chart for CSTL…
Fundamentals
About Castle Biosciences, Inc.
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
More in Diagnostics & Research
DHR
Danaher Corporation
$135B -16.0% YTD
IDXX
IDEXX Laboratories, Inc.
$43B -19.5% YTD
A
Agilent Technologies, Inc.
$39B 2.5% YTD
NTRA
Natera, Inc.
$38B 14.4% YTD
WAT
Waters Corporation
$37B -1.4% YTD
IQV
IQVIA Holdings, Inc.
$35B -7.7% YTD
ILMN
Illumina, Inc.
$29B 48.0% YTD
MTD
Mettler-Toledo International, I
$27B -4.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.